Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus

Expert Review of Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 351-363

  Vezzoli, Pamela ^a   Berti, Emilio ^b   Marzano, Angelo V ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Anti CD20 monoclonal antibody; Immunosuppressive drug; Intravenous immunoglobulin; Paraneoplastic autoimmune multiorgan syndrome; Paraneoplastic pemphigus; Rituximab; Systemic corticosteroid

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; AMENORRHEA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ASTHENIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS; CATARACT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CUSHING DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; IMMUNOPATHOGENESIS; INFECTION; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; PARANEOPLASTIC PEMPHIGUS; PATHOPHYSIOLOGY; PEMPHIGUS VULGARIS; PLASMAPHERESIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SKIN MANIFESTATION; STROKE; SYSTEMIC DISEASE; TACHYCARDIA; THROMBOCYTOPENIA; THYMOMA; THYMUS SURGERY; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 46149117265     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.3.351     Document Type: Review

References (106)

1. Anhalt GJ, Kim SC, Stanley JR et al. Paraneoplastic pemphigus, an autoimmune disease associated with neoplasia. N. Engl. J. Med. 323, 1729-1735 (1990).
2. Liu AY, Valenzuela R, Helm TN, Camisa C, Melton AL, Bergfeld WF. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J. Am. Acad Dermatol. 28, 696-699 (1993).
3. Anhalt GJ. Paraneoplastic pemphigus. J. Invest. Dermatol. Symp. Proc. 9, 29-33 (2004).
4. Joly P, Richard C, Gilbert D et al. Sensitivity and specificity of clinical, histologic and immunologic features in the diagnosis of paraneoplastic pemphigus. J. Am. Acad. Dermatol. 43, 619-626 (2000).
5. Nguyen VT, Ndoye A, Bassler KD et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome. Arch. Dermatol. 137, 193-207 (2001).
6. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J. Am. Acad. Dermatol. 40, 649-671 (1999).
7. Schlesinger T, McCarron K, Camisa C, Anhalt G. Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin's lymphoma. Cutis 61, 94-96 (1998).
8. Plumb R, Doolittle GC. Paraneoplastic pemphigus in a patient with non-Hodgkin's lymphoma. Am. J. Hematol. 52, 58-59 (1996).
9. Marzano AV, Grammatica A, Cozzani E, Terracina M, Berti E. Paraneoplastic pemphigus. A report of two cases associated with chronic B-cell lymphocytic leukaemia. Br. J. Dermatol. 145, 127-131(2001).
10. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology 190, 245-250 (1995).
11. Lemon MA, Weston WL, Huff JC. Childhood paraneoplastic pemphigus associated with Castleman's tumour. Br. J. Dermatol. 136, 115-117 (1997).
12. Kim SC, Chang SN, Lee IJ et al. Localized mucosal involvement in a young patient with paraneoplastic pemphigus associated with Casdeman's tumour. Br. J. Dermatol. 138, 667-671 (1998).
13. Wolff H, Kunte C, Messer G et al. Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumour. Br. J. Dermatol. 140, 313-316 (1999).
14. Lee IJ, Kim SC, Kim HS et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman's tumor. J. Am. Acad. Dermatol. 40, 294-297 (1999).
15. Irsutti M, Paul JL, Selves J, Railhac JJ. Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus. Eur. Radiol. 9, 1219-1221 (1999).
16. Chorzelski T, Hashimoto T, Maciejewska. B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman's tumor, myasthenia gravis and bronchiolitis obliterans. J. Am. Acad. Dermatol. 41, 393-400 (1999).
17. Hsiao CJ, Hsu MML, Lee JYY, Chen WC, Hsieh WC. Paraneoplastic pemphigus in association with a retroperitoneal Castleman's disease presenting with a lichen planus pemphigoides-like eruption. A case and review of literature. Br. J Dermatol. 144, 372-376 (2001).
18. Chin AC, Stich D, White FV, Radhacrishnan J, Holterman MJ. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: a rare case of Castleman's disease with respiratory failure requiring lung transplantation. J. Pediatr. Surg. 36, E22 (2001).
19. Fujimoto W, Kanehiro A, Kuwamoto-Hara K et al. Paraneoplastic pemphigus associated with Castleman's disease and asymptomatic bronchiolitis obliterans. Eur. J. Dermatol. 12, 355-359 (2002).
20. Wang L, Bu D, Yang Y, Chen X, Zhu H. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 363, 525-531 (2004).
21. Hinterhuber G, Drach J, Riedl E et al. Paraneoplastic pemphigus in association with hepatocellular carcinoma. J. Am. Acad. Dermatol. 49, 538-540 (2003).
22. Niimi Y, Kawana S, Hashimoto T, Kusunoki T. Paraneoplastic pemphigus associated with uterine carcinoma. J. Am. Acad. Dermatol. 48, S69-S72 (2003).
23. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis or non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 40(6), 553-562 (2004).
24. Anhalt GJ. Paraneoplastic pemphigus. Adv. Dermatol. 12, 77-96 (1997).
25. Younus J, Ahmed AR. The relationship of pemphigus to neoplasia. J. Am. Acad. Dermatol. 23, 498-502 (1990).
26. De Saint PG, Albes B, Bayle P, Lamant L, Bazex J. Cutaneous T-cell lymphoma, cutaneous hyperpigmentation and paraneoplastic pemphigus. Ann. Dermatol. Venereol. 129, 896-900 (2002).
27. Marzano AV, Vezzoli P, Mariotti F, Boneschi V, Caputo R, Berti E. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br. J. Dermatol. 153(1), 214-215 (2005).
28. Park GT, Lee JH, Yun SJ, Lee SC, Lee JB. Paraneoplastic pemphigus without an underlying neoplasm. Br. J. Dermatol. 156, 563-566 (2007)
29. Ostezan LB, Fabre VC, Caughman SW, Swerlick RA, Korman NJ, Callen JP. Paraneoplastic pemphigus in the absence of a known neoplasm. J. Am. Acad. Dermatol. 33, 312-315 (1995).
30. Mimouni D, Anhalt GJ, Lazarova Z et al. Paraneoplastic pemphigus in children and adolescents. Br. J. Dermatol. 147, 725-732 (2002).
31. Lane JE, Woody C, Davis LS, Guill MF, Jerath RS. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics 114, 513-516 (2004).
32. Wang J, Bu DF, Li T et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br. J. Dermatol. 153, 558-564 (2005).
33. Bowen GM, Peters NT, Fivenson DP et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenetic trigger of epitope spreading? Arch. Dermatol. 136, 652-656 (2000).
34. Chan LS. Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch. Dermatol. 136, 663-664 (2000).
35. Zhu X, Zhang B. Paraneoplastic pemphigus. J. Dermatol. 34, 503-511 (2007).
36. Zhang B, Zheng R, Wang J, Bu D, Zhu X. Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J. Invest. Dermatol. 126, 832-840 (2006).
37. +) T cells: a highly differentiated and apoptosis-prone population. Eur. J. Immunol. 31, 1122-1131 (2001).
38. Reich K, Brinck U, Letschert M et al. Graft-versus-host-disease-like immunophenotype and apoptotic keratinocyte in paraneoplastic pemphigus. Br. J. Dermatol. 141, 739-746 (1999).
39. Powell AM, Albert S, Oyama N, Sakuma-Oyama Y, Bhogal B, Black MM. Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegerans. JEADV 18, 360-364 (2004).
40. Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S. Paraneoplastic pemphigus: an association with fludarabine? Br. J. Dermatol. 144(66), 1255-1261 (2001).
41. Menenakos C, Braumann C, Hartmann C, Jacobi CA. Retroperitoneal Castleman's tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J. Surg. Oncol. 5, 45 (2007).
42. Nousari HC, Deterding R, Wojtczack H et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N. Engl. J. Med. 340, 1406-1410 (1999).
43. Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br. J. Dermatol. 149, 1143-1151 (2003).
44. Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies J. Am. Acad. Dermatol. 56, 153-159 (2007).
45. + T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease. N. Engl. J. Med. 24(349), 407-408 (2003).
46. Sun H, Wang R, Bin H et al. Localized Castleman's disease with paraneoplastic pemphigus and pulmonary involvement, clinical features and histopathology. Zhonghua Yi Xue Za Zhi 82, 530-533 (2002).
47. Heymann WR. Paraneoplastic autoimmune multiorgan syndrome. J. Am. Acad. Dermatol. 51, 631-632 (2004).
48. Wang J, Zhu X, Li R et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch. Dermatol. 141, 1285-1293 (2005).
49. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fisher A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358, 1511-1513 (2001).
50. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44, 2836-2840 (2001).
51. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952-957 (2001).
52. Grillo-Lopez AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1, 1-9 (2000).
53. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed. Pharmacother. 58, 299-309 (2004).
54. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17, 791-795 (1999).
55. Lowndes S, Darby A, Mead G et al. Stevens-Johnson syndrome after treatment with rituximab. Ann. Oncol. 13, 1948-1950 (2002).
56. + follicular lymphoma-associated paraneoplastic pemphigus. Arch. Dermatol. 137, 269-272 (2001).
57. Heizmann M, Itin P, Wernli M, Borradori L, Bargentzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am. J. Hematol. 66, 142-144 (2001).
58. Barnadas MA, Roe E, Brunet S et al. Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. JEADV 20, 69-74 (2006).
59. Vecchietti G, Kerl K, Hügli A, Samson J, Borradori L. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br. J. Dermatol. 148, 823-842 (2003).
60. Ahmed Razzaque A, Avram MM, Duncan LM. Case 23-2003: a 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N. Engl. J. Med. 349, 382-391 (2003).
61. Van Rossum MM, Verhaegen NT, Jonkman MF et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leukemia Lymphoma 45(11), 2327-2332 (2004).
62. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J. Drugs Dermatol. 2, 564-567 (2003).
63. Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin. Exp. Dermatol. 32, 172-175 (2007).
64. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55, 1062-1063 (2000).
65. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann. Intern. Med. 133, 275-279 (2000).
66. Shvidel L, Klepfish A, Berrebi A. Succesful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma. Am. J. Hematol. 67, 213-219 (2001).
67. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 214, 310-318 (2007).
68. Salopeck TG, Logsetty S, Tredger EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol. 47, 785-788 (2002).
69. España E, Fernández-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J. Am. Acad. Dermatol. 50, 974-976 (2004).
70. Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus -an update. Eur. J. Dermatol. 15, 224-230 (2005).
71. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur. J. Dermatol. 16, 266-270 (2006).
72. Niedermeier A, Eming R, Pfutze M et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol. 143, 192-198 (2007).
73. Schmidh E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol. 156, 352-356 (2007).
74. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus; vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772-1779 (2006).
75. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Eng. J. Med. 357, 545-552 (2007).
76. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and review of the literature. Arch. Dermatol. 143(8), 1033-1038 (2007).
77. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520-533 (2003).
78. Lehrnbecher T. [Intravenous immunoglobulins in the prevention of infection in children with hematologic-oncologic diseases.] Klin. Padiatr. 213(Suppl. 1), A103-A105 (2001).
79. Sullivan KM, Kopecky HJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323, 705-712 (1990).
80. Belgi AS, Azeez M, Hoyle C, Willams RE. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol. 153, 620-625 (2005).
81. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Clin. Exp. Dermatol. 28, 366-368 (2003).
82. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR, Correlation of peptide specificity and IgG subclass with pathogenic and non-pathogenic autoantibodies in pemphigus vulgaris. Proc. Natl Acad. Sci. USA 92, 5239-5243 (1995).
83. Harris DP, Haynes L, Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 6, 475-482 (2006).
84. Hertl M, Veldman C. T cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun. Rev. 2, 278-283 (2003).
85. Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin. Exp. Dermatol. 31, 503-508 (2006).
86. Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol. 163, 4284-4291 (1999).
87. Camisa C, Helm TN, Liu YC et al. Paraneoplastic pemphigus: a report of three cases including one long term survivor. J. Am. Acad. Dermatol. 27, 547-553 (1992).
88. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasias-induced autoimmune disease. Arch. Dermatol. 129, 883-885 (1993).
89. Tóth GG, van der Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. J. Eur. Acad. Dermatol. Venereol. 16(6), 607-611 (2002).
90. Dega H, Laporte JL, Joly P, Gabarre J, André C. Paraneoplastic pemphigus associated with Hodgkins disease. Br. J. Dermatol. 138, 196-198 (1998).
91. Martinez De Pablo MI, Iranzo P, Mascara JM, Llambrich A, Baradad M, Herrero C. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Dermatol. Venereol. 85, 233-235 (2005).
92. Beutner EH, Pelton S, Hashimoto T et al. A nonfatal case and 2 fatal cases of paraneoplastic pemphigus: can complement indirect immunofluorescent test help to identify fatal 'group A' paraneoplastic pemphigus cases? J. Am. Acad. Dermatol. 47, 841-851 (2002).
93. Williams JV, Marks JG JR, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br. J. Dermatol. 142, 506-508 (2000).
94. Herzberg MS, Schiffer M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am. J. Hematol. 63, 105-106 (2000).
95. Becker R, Bastian C, Wesselmann U, Karl S, Hamm H, Bröcker EB. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur. J. Dermatol. 8, 551-553 (1998).
96. Perniciaro C, Kuechle M, Colón-Otero G, Raymond MG, Spear KL, Pittelkow MR. Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin. Proc. 69, 851-855 (1994).
97. Nanda M, Nanda A, Al-Sabah H, Dvorak R, Alsaleh QA. Paraneoplastic pemphigus in association with B-cell lymphocytic leucemia and hepatitis C: favorable response to intravenous immunoglobulins; and prednisolone. Int. J. Dermatol. 46, 767-769 (2007).
98. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J. Am. Acad. Dermatol. 40, 750-754 (1999).
99. Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with Mycophenolic acid. J. Dermatol. Treat. 17, 370-376 (2006).
100. Proby C, Fujii Y, Owaribe K, Nishikawa T, Amagai M. Human autoantibodies against HD1/plectin in paraneoplastic pemphigus. J. Invest. Dermatol. 112, 153-156 (1999).
101. Izaki S, Yoshizawa Y, Kitamura K et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br. J. Dermatol. 134, 987-989 (1996).
102. Braess J. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). Ann. Hematol. 75, 227-230 (1997).
103. Hohwy T, Bang K, Steiniche T, Anker Peterslund N, D'Amore F. Alemtuzumab-induced remission of both severe paraneoplstic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur. J. Haematol. 73, 206-209 (2004).
104. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
105. Dupuy A, Viguier M, Bédane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol. 140, 91-96 (2004).
106. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis. 61, 922-924 (2002).